Table 4.
Study | Technique | Treatment site | Patients (n) | Total dose (Gy)/number of fractions |
Acute GI toxicity (%) |
Acute GU toxicity (%) |
|||||
---|---|---|---|---|---|---|---|---|---|---|---|
Prostate | Whole pelvis | Grade 3 | Grade 2 | p-value | Grade 3 | Grade 2 | p-value | ||||
Aizer et al31 | 3D-CRT, IMRT | WPRT | 68 | 75.6/42 | 45/25 | 10 | 34 | 0.048 | 2 | 18 | 0.090 |
PORT | 209 | – | 6 | 25 | 3 | 7 | |||||
Guckenberger et al28 | IMRT | WPRT | 25 | 73.91–76.23/32–33 | 46/25 | 0 | 12 | 1.00 | 0 | 44 | 0.81 |
PORT | 75 | – | 0 | 12 | 5 | 36 | |||||
Deville et al10 | IMRT | WPRT | 30 | 79.2/44 | 45/25 | 0 | 50 | 0.006 | 3 | 50 | 0.587 |
PORT | 30 | – | 0 | 13 | 0 | 50 | |||||
Current study | VMAT | WPRT | 119 | 78/39 | 46.8/26 | 0 | 14 | 0.066 | 0 | 13 | 0.620 |
PORT | 105 | – | 0 | 7 | 0 | 11 |
3D-CRT, three-dimensional conformal radiotherapy; GI, gastrointestinal; GU, genitourinary; IMRT, intensity-modulated radiotherapy; VMAT, volumetric-modulated arc therapy.